Literature DB >> 34526861

Current Advances in Hypertrophic Scar and Keloid Management.

Natasha Barone1, Tyler Safran2, Joshua Vorstenbosch2, Peter G Davison2, Sabrina Cugno2, Amanda M Murphy2,3.   

Abstract

Hypertrophic scars and keloids are caused by excessive tissue response to dermal injury due to local fibroblast proliferation and collagen overproduction. This response occurs because of pathologic wound healing due to dysregulation in the inflammatory, proliferative, and/or remodeling phase. Patients with hypertrophic scars or keloids report reduced quality of life, physical status, and psychological health. Hypertrophic scars or keloids will develop in 30 to 90% of individuals, and despite their prevalence, treatment remains a challenge. Of the treatments currently available for hypertrophic scars and keloids few have been adequately supported by studies with appropriate experimental design. Here, we aim to review the available literature to provide up-to-date information on the etiology, epidemiology, histology, pathophysiology, prevention, and management options available for the treatment of hypertrophic scars and keloids and highlight areas where further research is required. Thieme. All rights reserved.

Entities:  

Keywords:  fibrosis; hypertrophic scar; keloid; scarring

Year:  2021        PMID: 34526861      PMCID: PMC8432993          DOI: 10.1055/s-0041-1731461

Source DB:  PubMed          Journal:  Semin Plast Surg        ISSN: 1535-2188            Impact factor:   2.195


  104 in total

1.  Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid.

Authors:  M Naitoh; N Hosokawa; H Kubota; T Tanaka; H Shirane; M Sawada; Y Nishimura; K Nagata
Journal:  Biochem Biophys Res Commun       Date:  2001-02-09       Impact factor: 3.575

Review 2.  Intralesional treatment for keloids and hypertrophic scars: a review.

Authors:  Jennifer A Ledon; Jessica Savas; Katlein Franca; Anna Chacon; Keyvan Nouri
Journal:  Dermatol Surg       Date:  2013-11-13       Impact factor: 3.398

3.  Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Controlled Trial.

Authors:  Patricia L Danielsen; Suzanne M Rea; Fiona M Wood; Mark W Fear; Helena M Viola; Livia C Hool; Thilanee U Gankande; Mansour Alghamdi; Andrew W Stevenson; Mitali Manzur; Hilary J Wallace
Journal:  Acta Derm Venereol       Date:  2016-08-23       Impact factor: 4.437

Review 4.  Current progress in keloid research and treatment.

Authors:  Paris D Butler; Michael T Longaker; George P Yang
Journal:  J Am Coll Surg       Date:  2008-02-01       Impact factor: 6.113

Review 5.  Management of acne scarring, part II: a comparative review of non-laser-based, minimally invasive approaches.

Authors:  Lauren L Levy; Joshua A Zeichner
Journal:  Am J Clin Dermatol       Date:  2012-10-01       Impact factor: 7.403

6.  Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection.

Authors:  June Hyunkyung Lee; Seong Eon Kim; Ai-Young Lee
Journal:  Int J Dermatol       Date:  2008-02       Impact factor: 2.736

7.  Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months.

Authors:  Rei Ogawa; Kiyoshi Mitsuhashi; Hiko Hyakusoku; Tuguhiro Miyashita
Journal:  Plast Reconstr Surg       Date:  2003-02       Impact factor: 4.730

8.  Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids.

Authors:  Brian Berman; Joely Kaufman
Journal:  J Am Acad Dermatol       Date:  2002-10       Impact factor: 11.527

Review 9.  The Use of Chemotherapeutics for the Treatment of Keloid Scars.

Authors:  Christopher David Jones; Luke Guiot; Mike Samy; Mark Gorman; Hamid Tehrani
Journal:  Dermatol Reports       Date:  2015-05-21

Review 10.  The molecular basis of hypertrophic scars.

Authors:  Zhensen Zhu; Jie Ding; Edward E Tredget
Journal:  Burns Trauma       Date:  2016-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.